Quizartinib (AC220)

规格	库存	目录价	会员专享价	数量
5 mg	3-5days	￥450.00	登录后可见	- +
10 mg	3-5days	￥650.00	登录后可见	- +
25 mg	3-5days	￥950.00	登录后可见	- +

规格

库存

目录价

会员专享价

数量

5 mg

3-5days

￥450.00

登录后可见

- +

10 mg

3-5days

￥650.00

登录后可见

- +

25 mg

3-5days

￥950.00

登录后可见

- +

基本信息

英文名称	Quizartinib (AC220)
中文名称	奎扎替尼
CAS号	950769-58-1
分子式	C29H32N6O4S
分子量	560.67
外观	White to off-white powder
储存条件	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

产品详情

Quizartinib (formerly also know as AC-220; AC-010220, Vanflyta) is a novel, potent, 2nd-generation, and orally bioavailable FLT3 tyrosine kinase inhibitor for Flt3 (ITD/WT) with potential anticancer activity.With IC50s of 1.1 nM and 4.2 nM, respectively, it inhibits FLT3 in MV4-11 and RS4EL11 cells. With respect to KIT, PDGFRα, PDGFRβ, RET, and CSF-1R, it demonstrates a ten-fold greater selectivity. Currently, Daiichi Sankyo is developing quizartinib to treat acute myeloid leukemia. Quizartinib (Vanflyta) was approved in 2023 by FDA for treating AML.

奎扎替尼

Quizartinib (AC220)

化学品安全说明书(MSDS)